Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.

Inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study * Patients with histologically or cytologically confirmed and documented r/r GBM that has progressed after prior radiation therapy and have not received prior bevacizumab OR patients with BC that has metastasized to the brain and who should have at least one newly diagnosed brain metastasis that has not been resected or irradiated, or has been irradiated and progressed OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic GEA (i.e., adenocarcinoma of the stomach (intestinal subtype), esophagus, or gastroesophageal junction), either untreated or r/r after one or more lines of treatment OR patients with histologically or cytologically confirmed and documented locally advanced or metastatic PDAC, either untreated or r/r after one or more lines of treatment. Exclusion Criteria: * Creatinine clearance (calculated using Cockcroft-Gault formula) \<40 mL/min. * Unmanageable bladder outflow obstruction or urinary incontinence. * QTcF \> 480 msec on screening ECG or congenital long QT syndrome. * Any condition that requires chronic treatment with anticoagulants or antiplatelet agents * Patients with a known bleeding disorder * Administration of a radiopharmaceutical within a period corresponding to 10 half-lives of the radionuclide used prior to injection of \[68Ga\]-FF58. * Pregnant women. Women who are breastfeeding must express and …